BioSpace News Archive

The virology market size was USD 2.06 billion in 2021 and is expected to register a revenue CAGR of 5.0% over the forecast period.

The global protein expression market size was USD 2.20 Billion in 2020 and is expected to register a revenue CAGR of 13.5% during the forecast period.

The global orthobiologics market size was USD 5.58 Billion in 2020 and is expected to register a CAGR of 5.1% during the forecast period.

Carisma Therapeutics Inc. presented at the Society for Immunotherapy of Cancer 37th Annual Meeting additional findings from its CT-0508 chimeric antigen receptor macrophage clinical trial for patients with advanced metastatic human epidermal growth factor receptor 2 overexpressing solid tumors, supporting a favorable safety profile and manufacturing feasibility of its proprietary engineered cell therapy platform.

DENTSPLY SIRONA Inc. announced its participation at upcoming conferences.

The National Kidney Foundation is pleased to announce that Dr. Kirk Campbell, the Irene and Dr. Arthur M. Fishberg Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Vice Chair of the Department of Medicine for Diversity, Equity, and Inclusion, has begun his two-year term as President Elect of NKF’s National Board of Directors.

ProKidney Corp., a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, announced that Dr. Tim Bertram, Chief Executive Officer, will participate in the following upcoming investor conferences.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the first quarter of fiscal year 2023, ended September 30, 2022.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent® (dupilumab) in the European Union (EU) to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.

Intensity Therapeutics, Inc. announced that data from its ongoing phase 1/2 clinical trial demonstrating the efficacy and tolerability of INT230-6 will be presented today at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting being held in Boston and virtually November 8-12, 2022.